We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
LSNE Completes Successful FDA PAI for Sterile Drug Product
News

LSNE Completes Successful FDA PAI for Sterile Drug Product

LSNE Completes Successful FDA PAI for Sterile Drug Product
News

LSNE Completes Successful FDA PAI for Sterile Drug Product

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "LSNE Completes Successful FDA PAI for Sterile Drug Product"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lyophilization Services of New England, Inc. (LSNE) has announced that they have completed a successful Pre-Approval Inspection (PAI) and General GMP Inspection in April 2015. This inspection clears the way for the 25 Commerce Drive manufacturing site, located in Bedford, NH, to manufacture commercial drug product for US distribution.

The inspection concluded with a recommendation for approval and the Establishment Inspection Report (EIR) has been received. This is the second PAI at the Commerce Drive facility, the first inspection was for a bulk drug intermediate lyophilized in LSNE’s 260 square foot lyophilizer.

Shawn Cain, Chief Operating Officer of LSNE stated, “The completion of this inspection is a critical milestone for LSNE as it is the first PAI for a sterile product at the 25 Commerce Road facility. This is also our second site to now be successfully inspected by the FDA to produce commercial products in the past few months. This demonstrates LSNE’s commitment to meeting all applicable regulatory standards for the production of commercial medical devices, bulk intermediates and sterile injectable drugs. It is only through the talent and dedication of our staff that we have been able to achieve and maintain this level of compliance.”

LSNE has also added additional capabilities across their three sites and they plan to continue expanding in the coming year(s). The 2015 master plan includes expansion of QC analytical testing capabilities, ICH stability chambers, additional complex formulation capabilities, as well as adding increased manufacturing capacity.

LSNE continues its path towards becoming the premier turn-key CMO for its clinical and commercial clients and its commitment to reduce the time and cost of bringing client projects from bench to market.

Advertisement